The European Medicines Agency (EMA) has issued a positive opinion recommending that retifanlimab (Zynyz) be approved for an expanded indication to treat adults with advanced squamous cell carcinoma of the…
June 2025 marked a month of significant progress in cancer care, as the FDA approved several new therapies and treatment combinations across a range of cancer types. As reported by…
Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…
Sometimes it can be difficult to target and treat cancer without harming healthy tissue. Even while surgically removing tumors, it is possible to accidentally hurt or damage healthy tissue,…
So far, the Phase 2 EMPOWER-CSCC-1 clinical study has evaluated cemiplimab (also known as Libtayo) in individuals with locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC). Data from…
Both Libtayo (cemiplimab) and Keytruda (pembrolizumab) have been shown to be beneficial treatment options for patients with locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC). But could Opdivo (nivolumab)…
According to a story from Neuro Central, pharmaceutical company Merck has provided an update on its findings from its phase 3 clinical trial KEYNOTE-412. This clinical trial was evaluating pembrolizumab…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
Even though a drug is sometimes developed with a certain condition in mind, it can be used to effectively treat or manage alternate conditions. For example, pembrolizumab (KEYTRUDA) is…
Head and neck squamous cell carcinoma (SCC) is considered both aggressive and difficult to treat. In fact, doctors estimate that nearly 50% of all patients will eventually see the recurrence…
Libtayo, a product of Regeneron Pharmaceuticals, has shown positive results in the treatment of those with advanced cutaneous squamous cell carcinoma. This data comes from a Phase 2 trial and…
A three cohort trial of STP705, a treatment for squamous cell carcinoma, has met its primary endpoint. This treatment is administered in a series of injections, offering an alternative to…
According to a story from the ASCO Post, the US Food and Drug Administration (FDA) first approved the drug pembrolizumab as a treatment for advanced esophageal squamous cell carcinoma on…
According to a story from drugs.com, the pharmaceutical company Merck recently announced that the US Food and Drug Administration (FDA) has approved its drug pembrolizumab (marketed as Keytruda) as a…
According to a story from EurekAlert!, a new type of cancer drug that is being described as a "Trojan horse" that infiltrates cancer tumors is showing potential in several types…
According to a story from PR Newswire, the biopharmaceutical company Soligenix, Inc. recently announced that it has received a patent in the EU for the company's innate defense regulator drug…
Epidermolysis Bullosa Epidermolysis Bullosa (EB) refers to a group of rare conditions which are characterized by fragile skin. Basically, the disease is caused by separation between the layers of the skin.…
The following story includes discussion of suicide. According to a story from EurekAlert!, a recent study has revealed that survivors of head and neck cancer are four times more likely…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
